See more : American Picture House Corporation (APHP) Income Statement Analysis – Financial Results
Complete financial analysis of BrainsWay Ltd. (BWAY) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of BrainsWay Ltd., a leading company in the Medical – Devices industry within the Healthcare sector.
You may be interested
- Yamazaki Baking Co., Ltd. (2212.T) Income Statement Analysis – Financial Results
- Zodiac Ventures Limited (ZODIACVEN.BO) Income Statement Analysis – Financial Results
- Harmonic Drive Systems Inc. (HSYDF) Income Statement Analysis – Financial Results
- Ohmoto Gumi Co., Ltd. (1793.T) Income Statement Analysis – Financial Results
- Public Joint Stock Company RussNeft (RNFT.ME) Income Statement Analysis – Financial Results
BrainsWay Ltd. (BWAY)
About BrainsWay Ltd.
Brainsway Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States, Europe, Israel, and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases. The company primarily serves doctors, hospitals, and medical centers in the field of psychiatry. Brainsway Ltd. was founded in 2003 and is headquartered in Jerusalem, Israel.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 31.79M | 27.18M | 29.66M | 22.06M | 23.10M | 16.40M | 11.15M | 11.52M | 6.80M | 3.38M | 1.19M | 364.25K |
| Cost of Revenue | 8.31M | 7.13M | 6.60M | 5.06M | 5.13M | 3.59M | 2.60M | 2.43M | 1.47M | 656.00K | 199.00K | 46.07K |
| Gross Profit | 23.48M | 20.05M | 23.06M | 17.00M | 17.97M | 12.81M | 8.55M | 9.10M | 5.33M | 2.72M | 990.00K | 318.18K |
| Gross Profit Ratio | 73.86% | 73.77% | 77.75% | 77.07% | 77.80% | 78.11% | 76.72% | 78.94% | 78.44% | 80.59% | 83.26% | 87.35% |
| Research & Development | 6.67M | 7.68M | 6.39M | 5.82M | 7.88M | 6.16M | 5.34M | 3.79M | 4.10M | 6.44M | 3.69M | 5.97M |
| General & Administrative | 5.32M | 6.85M | 5.78M | 4.72M | 4.39M | 8.23M | 7.47M | 5.74M | 3.61M | 2.34M | 1.43M | 1.31M |
| Selling & Marketing | 16.46M | 18.20M | 15.88M | 11.28M | 13.27M | 3.11M | 1.83M | 1.21M | 1.93M | 1.21M | 633.00K | 140.34K |
| SG&A | 21.64M | 25.05M | 21.66M | 16.01M | 17.66M | 11.34M | 9.30M | 6.95M | 5.54M | 3.55M | 2.06M | 1.45M |
| Other Expenses | 133.00K | 0.00 | 0.00 | 0.00 | 916.00K | 427.00K | 523.00K | 426.00K | 200.00K | 11.00K | -504.00K | 0.00 |
| Operating Expenses | 28.44M | 32.73M | 28.06M | 21.83M | 26.45M | 17.92M | 15.16M | 11.17M | 9.84M | 10.00M | 5.26M | 5.95M |
| Cost & Expenses | 36.74M | 39.86M | 34.66M | 26.89M | 31.58M | 21.51M | 17.76M | 13.59M | 11.31M | 10.66M | 5.46M | 5.99M |
| Interest Income | 2.17M | 1.11M | 225.00K | 61.00K | 175.00K | 44.00K | 22.00K | 12.00K | 18.00K | 93.00K | 304.00K | 288.19K |
| Interest Expense | 48.00K | 46.00K | 1.42M | 319.00K | 398.00K | 354.00K | 360.00K | 404.00K | 98.00K | 525.00K | 283.00K | 0.00 |
| Depreciation & Amortization | 1.34M | 1.53M | 1.69M | 1.62M | 2.80M | 1.23M | 1.07M | 649.00K | 611.00K | 336.00K | 206.00K | 109.28K |
| EBITDA | -2.56M | -11.45M | -4.67M | -3.46M | -6.58M | -4.40M | -5.56M | -1.34M | -3.38M | -5.68M | -4.06M | -5.57M |
| EBITDA Ratio | -8.06% | -41.02% | -11.17% | -21.89% | -28.50% | -26.85% | -49.92% | -12.75% | -57.54% | -203.22% | -79.98% | -1,530.22% |
| Operating Income | -4.96M | -12.68M | -5.00M | -4.83M | -8.48M | -5.11M | -6.61M | -2.07M | -4.51M | -7.28M | -4.27M | -5.68M |
| Operating Income Ratio | -15.60% | -46.67% | -16.86% | -21.89% | -36.69% | -31.19% | -59.32% | -17.95% | -66.25% | -215.30% | -358.87% | -1,560.22% |
| Total Other Income/Expenses | 1.01M | -351.00K | -1.42M | -319.00K | -1.43M | -1.16M | -274.00K | -328.00K | 418.00K | 732.00K | -2.83M | -233.28K |
| Income Before Tax | -3.95M | -13.03M | -6.42M | -5.15M | -9.91M | -6.27M | -6.89M | -2.40M | -4.09M | -6.55M | -7.09M | -5.92M |
| Income Before Tax Ratio | -12.41% | -47.96% | -21.64% | -23.34% | -42.88% | -38.24% | -61.78% | -20.80% | -60.10% | -193.64% | -596.64% | -1,624.27% |
| Income Tax Expense | 251.00K | 315.00K | 43.00K | 237.00K | 422.00K | 209.00K | 169.00K | 404.00K | 98.00K | 525.00K | 28.00K | 0.00 |
| Net Income | -4.20M | -13.35M | -6.46M | -5.39M | -10.33M | -6.48M | -7.05M | -2.40M | -4.09M | -6.55M | -7.12M | -5.92M |
| Net Income Ratio | -13.20% | -49.12% | -21.79% | -24.41% | -44.71% | -39.51% | -63.29% | -20.80% | -60.10% | -193.64% | -598.99% | -1,624.27% |
| EPS | -0.13 | -0.43 | -0.21 | -0.24 | -0.50 | -0.39 | -0.48 | -0.17 | -0.28 | -0.46 | -0.55 | -0.49 |
| EPS Diluted | -0.13 | -0.43 | -0.21 | -0.24 | -0.50 | -0.39 | -0.48 | -0.17 | -0.28 | -0.46 | -0.55 | -0.49 |
| Weighted Avg Shares Out | 33.16M | 30.77M | 31.15M | 22.44M | 20.51M | 16.64M | 14.77M | 14.17M | 14.46M | 14.16M | 12.87M | 12.17M |
| Weighted Avg Shares Out (Dil) | 33.16M | 30.77M | 31.15M | 22.44M | 20.51M | 16.64M | 14.77M | 14.51M | 14.46M | 14.26M | 12.87M | 12.17M |
BrainsWay Broadens Partnership with Katie's Way Plus Through Order of an Additional 18 Deep TMS™ Systems
Katie's Way Provides Lifesaving Mental Health Treatment Nationally with a Focus on Servicemembers, Veterans, and their Families Katie's Way Provides Lifesaving Mental Health Treatment Nationally with a Focus on Servicemembers, Veterans, and their Families
Low-Priced, High-Potential: 7 Cheap Stocks Under $10 to Try Your Luck With
Generally speaking, you want to minimize your exposure to cheap stocks under $10. Yes, smaller companies have the potential to rise dramatically higher than their larger counterparts.
Best Momentum Stocks to Buy for March 11th
BWAY, WILYY and CRH made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on March 11, 2024.
New Strong Buy Stocks for March 11th
BWAY, WILLY, IDCC, BRKL and SBSI have been added to the Zacks Rank #1 (Strong Buy) List on March 11, 2024.
BrainsWay Reports Fourth Quarter and Full-Year 2023 Financial Results and Operational Highlights
Generated Record Revenues with Robust 50% Year-over-Year Revenue Growth in Q4 2023; Generated Positive Quarterly Net Income
What's in the Offing for Brainsway (BWAY) in Q4 Earnings?
Brainsway's (BWAY) fourth-quarter 2023 performance is likely to have been impacted by the strong momentum across the entire business.
BrainsWay to Report Fourth Quarter and Full Year 2023 Financial Results on March 6, 2024
BURLINGTON, Mass. and JERUSALEM, Feb. 21, 2024 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced that it will report its fourth...
7 High-Growth Stocks to Snag for Spectacular Returns in 2024
In the stock market, pursuing high-growth stocks becomes a compelling venture, akin to searching for pearls in the vast sea of possibilities. The year 2024 unfolds with promises of prosperity and strategic opportunities, and within this realm, seven stocks emerge...
Biotech Stocks Are on Fire: Here Are the Top 3 Picks for January
From CRISPR gene editing to modify ideal agricultural traits, synthetic biology to promote eco-friendly engineering, or even that relating to biofuels, the field of biotechnology, also known as biotech, offers exciting disruptive solutions with the potential to expand to market...
5 Stocks With Recent Price Strength in a Volatile Market
Investors target stocks that are witnessing a bullish run. Some of the stocks seeing price strength are VTSI, USAP, TAST, BWAY, VIRC.
Source: https://incomestatements.info
Category: Stock Reports